Evidence map›Paper›PMID 34704193›Full record

ArticleAdvances in therapy2021

Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia.

Ricardo Viana, Denise D'Alessio, Laura Grant, Nichola Cooper, Donald Arnold, Mervyn Morgan, Drew Provan, Adam Cuker, Quentin A Hill, Yoshiaki Tomiyama and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Advances in therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 6 countries.

Ricardo VianaNovartis Pharma AG, Basel, Switzerland.
Denise D'AlessioNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Laura GrantAdelphi Values Ltd, Adelphi Mill, Grimshaw Lane, Bollington, Cheshire, SK10 5JB, UK. laura.grant@adelphivalues.com.ORCID 0000-0002-4291-931X
Nichola CooperDepartment of Haematology, Hammersmith Hospital, Imperial College London, London, UK.
Donald ArnoldDepartment of Medicine, McMaster Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada.
Mervyn MorganITP Support Association, Bolnhurst, UK.
Drew ProvanAcademic Haematology Unit, Blizard Institute, Barts and The School of Medicine and Dentistry, London, UK.
Adam CukerDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Quentin A HillLeeds Teaching Hospital NHS Trust, St James' University Hospital, Leeds, UK.
Yoshiaki TomiyamaDepartment of Blood Transfusion, Osaka University Hospital, Suita, Japan.
Waleed GhanimaOstfold Hospital Trust, Gralum, Norway.
Adelphi Group (United Kingdom) · GBHammersmith Hospital · GBMcMaster University · CANovartis (Switzerland) · CHNovartis (United States) · USOsaka University Hospital · JPQueen Mary University of London · GBSt James's University Hospital · GBUniversity of Oslo · NOUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionImmune thrombocytopenia (ITP) is an autoimmune disorder caused by immunologic destruction of otherwise normal platelets. Patients and physicians differ in their views pertaining to the limitations imposed on patients' daily lives by ITP and its treatment. Poor understanding of ITP symptoms can result in misdiagnosis and complex treatment patterns, and affect patient health-related quality of life (HRQoL). The ITP Life Quality Index (ILQI) is a 10-item patient-reported outcome measure developed for clinical practice to aid discussions between patients and physicians. This research aimed to validate the psychometric properties of the ILQI using data collected in the ITP World Impact Survey (I-WISh).

methodsI-WISh data containing responses to the ILQI from 1507 patients with ITP across 13 countries worldwide was subject to psychometric analysis to evaluate the structure, reliability and validity of the ILQI and assess scoring cut-offs.

resultsThe ILQI has an overarching unidimensional structure, supporting a total score including all 10 items. Reliability was supported (Cronbach's alpha = 0.90). ILQI scores monotonically increased with ITP severity. ILQI scores correlated with measures of fatigue and emotional well-being, supporting construct validity. Differential item functioning (DIF) analyses showed that ILQI item responses were interpreted similarly between the USA and other Western countries. It was suggested that previous clinical cut-off score of 20 for "impaired HRQoL" was reduced to 17 and a cut-off of 23-25 (rather than 30) was suggested to assess "significantly impaired HRQoL".

conclusionThe validity and reliability of the ILQI to assess HRQoL of patients with ITP is supported. The revised cut-off scores for the ILQI will aid patient-centric decision-making.

Indexed as

Purpura, Thrombocytopenic, IdiopathicQuality of LifeHumansPsychometricsReproducibility of ResultsSurveys and QuestionnairesHealth related quality of life (HRQoL)Immune thrombocytopenia (ITP)ITP Life Quality Index (ILQI)ITP World Impact Survey (I-WISh)Psychometric evaluationTool for clinical practice

Identifiers

PMID34704193
PMCPMC8572218
OpenAlexW3209198105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.